About Uniqure NV
uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease. Its product candidates include AMT-060 for Hemophilia B, AMT-110 for Sanfilippo B Syndrome, AAV2/GDNF for Parkinson's Disease, S100A1 for Congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). For the AMT-060, the Company is conducting a Phase I/II clinical trial. The AMT-110 is based on glial cell line-derived neurotrophic factor, which is being studied in an investigator-sponsored Phase I clinical study. The AMT-130 is used for the treatment of Huntington's disease, in which the Company has demonstrated preclinical proof of concept.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: QURE
- Previous Close: $6.14
- 50 Day Moving Average: $5.98
- 200 Day Moving Average: $6.91
- 52-Week Range: $5.25 - $15.75
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.45
- P/E Growth: 0.00
- Market Cap: $154.34M
- Outstanding Shares: 25,136,000
- Beta: 0.15
- Net Margins: -370.57%
- Return on Equity: -70.75%
- Return on Assets: -30.99%
Companies Related to Uniqure NV:
- Debt-to-Equity Ratio: 0.25%
- Current Ratio: 7.34%
- Quick Ratio: 7.33%
What is Uniqure NV's stock symbol?
Uniqure NV trades on the NASDAQ under the ticker symbol "QURE."
Where is Uniqure NV's stock going? Where will Uniqure NV's stock price be in 2017?
8 brokers have issued 1-year price targets for Uniqure NV's stock. Their forecasts range from $8.00 to $27.00. On average, they expect Uniqure NV's share price to reach $16.57 in the next twelve months.
When will Uniqure NV announce their earnings?
Uniqure NV is scheduled to release their next quarterly earnings announcement on Monday, April, 3rd 2017.
Who owns Uniqure NV stock?
Uniqure NV's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (5.04%), FMR LLC (4.68%), Putnam Investments LLC (1.30%), City Financial Investment Co Ltd (1.06%), Renaissance Technologies LLC (1.00%) and FT Options LLC (0.26%).
Who sold Uniqure NV stock? Who is selling Uniqure NV stock?
Uniqure NV's stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC.
Who bought Uniqure NV stock? Who is buying Uniqure NV stock?
Uniqure NV's stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, City Financial Investment Co Ltd, FMR LLC, FT Options LLC, Commonwealth of Pennsylvania Public School Empls Retrmt SYS and Renaissance Technologies LLC.
How do I buy Uniqure NV stock?
Shares of Uniqure NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Uniqure NV stock cost?
One share of Uniqure NV stock can currently be purchased for approximately $6.14.